Cannabidiol for at risk for psychosis youth: A randomized controlled trial

Background No biological treatment has been firmly established for the at‐risk stage of psychotic disorder. In this study we aim to test if subthreshold psychotic symptoms can be effectively treated with cannabidiol (CBD), a non‐psychoactive compound of the plant Cannabis sativa. The question has ta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Early intervention in psychiatry 2022-04, Vol.16 (4), p.419-432
Hauptverfasser:	Amminger, G. Paul, Lin, Ashleigh, Kerr, Melissa, Weller, Amber, Spark, Jessica, Pugh, Charlotte, O'Callaghan, Sally, Berger, Maximus, Clark, Scott R., Scott, James G., Baker, Andrea, McGregor, Iain, Cotter, David, Sarnyai, Zoltan, Thompson, Andrew, Yung, Alison R., O'Donoghue, Brian, Killackey, Eoin, Mihalopoulos, Cathy, Yuen, Hok Pan, Nelson, Barnaby, McGorry, Patrick D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adolescent Adult Cannabidiol Cannabidiol - therapeutic use Cannabis Child Child & adolescent psychiatry Clinical trials Humans Psychosis Psychotic Disorders - diagnosis Questions RCT ultra‐high risk Young Adult youth
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!